Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors

Ard van Veelen, Shahab Abtahi, Patrick Souverein, Johanna H M Driessen, Olaf H Klungel, Anne-Marie C Dingemans, Robin van Geel, Frank de Vries, Sander Croes

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number102149
Number of pages8
JournalCancer Epidemiology
Volume78
Early online date13 Apr 2022
DOIs
Publication statusPublished - Jun 2022

Keywords

  • CPRD
  • DATABASE
  • Immune checkpoint inhibitors
  • Lung cancer
  • PRIMARY-CARE
  • Study eligibility
  • Tyrosine kinase inhibitors

Cite this